Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
multi-target peptide vaccine
- Development stage
- Preclinical
- Lead developer
- Hebei Bio-High Technology Development
- Modality
- Vaccines & Immunotherapeutics, Peptides
- Administration
- Subcutaneous, Intradermal
01
Overview
Multi-target peptide vaccine is a preclinical therapeutic cancer vaccine candidate under development by Hebei Bio-High Technology Development, in collaboration with Jiuzhou Pharmaceutical and the research team of Professor Yu Jun at The Chinese University of Hong Kong. The vaccine is designed to target gastrointestinal tumors by incorporating multiple tumor-associated peptide antigens intended to stimulate a specific anti-tumor immune response. The program is currently in the preclinical stage, focusing on identifying and validating optimal peptide targets for gastrointestinal malignancies.
- Other names
- 多肽疫苗类药物gastrointestinal tumor peptide vaccine
02
Targets
γδ TCR (T-cell receptor)Major histocompatibility complex peptide-binding groove
Beyond the preview
Go deeper on multi-target peptide vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on multi-target peptide vaccine.